US NEUROLOGY – VOLUME 14 ISSUE 2 – FALL 2018
Welcome to the latest edition of US Neurology!
This edition features a wide range of expert interviews, case reports, and original research, exploring the latest developments in neurological disorders. We hope this edition is of interest both to neurologists and the wider medical community. Our expert interviews continue to be a popular feature, providing concise commentaries from key opinion leaders. In an original research study, Mayer et al. explore healthcare resource utilization costs in patients with Duchenne muscular dystrophy covered by government (Medicaid) and non-government (private) health plans. The case reports provide unique insights in diagnosis, therapeutics, and pathophysiology of neurologic disease, particularly in rare disorders where correct diagnosis is often delayed, preventing optimal treatment.
This edition also features a supplement that tells the fascinating story of Dr Geoffrey Guy’s work on gaining the acceptance of the medical community of the therapeutic potential of cannabinoids. The approach, considered highly controversial in 1998, has led to the US Food and Drug Administration approval earlier this year of Epidiolex®, the first cannabis-derived medication to be approved as a prescription medicine in the US.
Enjoy and happy reading!